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Abstract
Atopic dermatitis (AD) is an inflammatory, recurrent and chronic disease that 
occurs in 2–10% of the population. Therapy of AD could be divided into topical 
(corticosteroids, calcineurin inhibitors) and systemic (cyclosporine, methotrexate, 
azathioprine or biological treatment). Phototherapy is taken into consideration 
as a second-line treatment, when topical therapy is unsuccessful. We distinguish 
many types of phototherapy, e.g. narrowband UVB (311–313 nm), UVA-1 therapy 
(340–400 nm), UVA/B combination, UVA therapy plus 8-methoxypsoralens 
(PUVA), 308 nm excimer laser (EL) and blue light. Phototherapy is effective in 
many cases, whether in adults or in children. It should be remembered that during 
therapy possible side effects may occur. Among them the risk of carcinogenesis is 
the most severe.
Keywords: atopic dermatitis, phototherapy, eczema, NB-UVB therapy,  
UVA-1 therapy PUVA therapy, blue light
1. Introduction
Atopy refers to a personal tendency to heightened immune responses to small 
doses of allergens and as a result producing IgE antibodies. As a consequence a 
patient develops certain types of diseases, such as atopic dermatitis, allergic rhinitis 
and asthma.
Atopic dermatitis (AD) is a dermatosis that occurs in 2–5% of the population 
and is one of the most common dermatoses. Nowadays in developed countries over 
the past three decades the number of cases of AD has almost tripled. The main 
symptoms of the disease are pruritis, abnormally dry skin and erythema. Atopic 
dermatitis is characterized by chronic or relapsing course. The onset of AD in 
most cases is observed during early childhood. In infants, lesions appear mostly 
on cheeks and extremities, whereas in children and adults – in flexural areas. The 
lesions are combined with hyperkeratosis and lichenification. Triggering factors 
such as stress, wool intolerance or sweating may worsen the course of AD. During 
therapy avoiding those is highly desirable. Staphylococcus aureus is one of the micro-
organisms which can be found on the skin of AD patients. It is present not only on 
erythematous lesions, but also on a “healthy” skin.
The first line of AD therapy is a short-term regimen – when the patient uses 
medicines only when inflammatory lesions occur, but in recent years the therapy 
is more focused on proactive and long-term maintenance. Drugs should be applied 
continuously or one/two times a week. The basic rule in the therapy is to use emol-
lients which restore epidermal barrier and create an occluding coating. Therefore, 
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they protect the skin from triggering factors. In mild course of AD using topical 
corticosteroids and topical calcineurin inhibitors is recommended. In moderate 
to severe cases of AD phototherapy, cyclosporine, methotrexate, azathioprine or 
systemic corticosteroids may be administered. Phototherapy (using ultraviolet light) 
is also useful in other inflammatory skin diseases, like psoriasis. We distinguish the 
following types of phototherapy:
• broadband UVB (290–320 nm),
• narrowband UVB (311–313 nm),
• UVA-1 therapy (340–400 nm),
• UVA therapy plus 8-methoxypsoralens (PUVA),
• 308 nm excimer laser (EL),
• blue light (BL).
2. Mechanism of action
Phototherapy (specifically broadband UVB) in atopic dermatitis has been used 
since 1970 and its effectiveness is clinically proven [1]. The mechanism of skin 
lesions development in atopic dermatitis is connected with activation of T-cell infil-
tration into the skin, which leads to increasing proliferation of keratinocytes and as 
a result thickening of the skin. Th2 cells accumulate and produce various cytokines, 
such as IL-4, IL-31, IL-13. Th1 cells, INF- γ, Th22 cells and IL-22 were also found 
in chronic atopic lesions [2]. Common type of drugs used in AD are immunosup-
pressants. We divide them into systemic (cyclosporine) and topical (tacrolimus, 
pimecrolimus) types. They act by inhibiting calcineurin which leads to a decrease in 
activation of T cells. It indicates that targeting T cells may be an effective approach 
in therapy of AD.
Artificial or natural ultraviolet radiation leads to deep immunosuppression 
which induces apoptic death in activated T cells. Many factors, such as wavelength, 
dosage of radiation, amount of UV sessions have an impact on the intensity of 
immunosuppressive effect of UV radiation. In general UV radiation could be dived 
into UVB (with wavelength between 280 and 320 nm) and UVA (with wavelength 
between 320 and 400 nm). Overall UVB light has a higher immunosuppressive 
impact than UVA. Psoralens in PUVA therapy are molecules whose purpose is 
intercalation of DNA. After UVA radiation psoralens are binding to the DNA. This 
results in stopping cells proliferation [3]. Nowadays more and more diseases are 
treated with biological therapy. Owing to good safety profile, accessibility, only 
topical immunosuppression and cost-effectiveness of UV radiation, phototherapy 
is still a very popular AD therapy. Biological effects of UV radiation are complex 
and could be classified into instantaneous and delayed [4]. Damage of DNA and 
cytoplasmic membrane, induction of cytoplasmic transcriptional factors and chro-
mophore’s isomerization initiates immediate stunted growth and, as a consequence, 
apoptosis [5].
After UVB radiation, photon’s absorption causes changes of DNA molecular 
structures. As a result, transcription of DNA is paused and cell cycle in fibroblasts 
and epidermal cells stops (phototype I reaction) [6]. In PUVA phototherapy after 
psoralen application with following UVA radiation, reactive oxygen species are 
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damaging DNA and cell membrane (phototype II reaction) [7]. After only one hour 
DNA starts to repair and the cells start to proliferate. As an effect in 48–72 hours 
after UV radiation short-term effects are reversing. Long term effects refer to 
inhibition of immune cells which causes immunosuppression. Induction of apoptosis 
in epidermal and dermal T cells is a crucial mechanism [8]. Apoptosis after UVB 
radiation concerns keratinocytes too, leading to lesions clearance. Moreover, UVB 
and PUVA activate T regulatory (Treg) cells and decrease the amount of presenting 
antigen in Langerhans cells [9].
After UV radiation cytokine secretion and number of macrophages are limited. 
Acting through reactive oxygen species, neutrophils and NK cells are suppressed 
[10]. As an effect cytokine balance is changed – decrease of inflammatory cytokines 
IL-2, IL-8, IL-9, IL-17, IL-22, IL-23, TNF-a and IFN- γ with simultaneous induction 
of immunosuppressive cytokine – IL-10 [11].
3. Types
3.1 NB-UVB
NB UV-B has been in use of AD treatment since 1990 [28]. It emits highly selec-
tive UV-B light wavelengths (from 311 to 313 nm, without shortwave length UVB) 
[12]. Sunburning potential of NB UV-B is evidently lower than broadband UV-B (BB 
UV-B) [13]. Due to the long list of advantages, like safety profile, effectiveness, acces-
sibility NB UV-B could be pondered as a first-line treatment [14]. It has been estab-
lished in many randomized trials that NB-UVB therapy improved the scores of AD 
and the necessity for applying potent topical corticosteroids was reduced [15]. These 
type of positive results remained up to six months after the scheme of NB-UVB was 
finished [16]. Contrary to UVA, NB UV-B does not penetrate the dermis, therefore it 
is limited to the epidermis [15]. Patient’s tolerance to UV radiation and pigmenta-
tion of the skin determines the dosage of UV-B. When it comes to the methods of 
adjusting UV-B dose which should be administered, the most popular is defining 
“Minimal Erythema Dose” (MED). MED refers to the smallest UV-B dose which is 
capable of provoking minimal erythema on the patient’s skin [17]. Skin phototype 
can play a role in determining UV-B dosage. Measuring skin reflectance is another 
way of UV-B dose calculation and it was derived from defining the skin pigmenta-
tion. It is called reflectance-guided UV-B and recently it has become highly popular 
[18]. Most physicians use NB UV-B treatment schedule which consists of three 
sessions of radiation every six weeks [19]. In early studies, researchers used nearly 
erythemogenic dose of NB UV-B, but recently it was proven, that reducing a dose 
by half can give similar outcome, higher tolerance and lower risk of carcinogenesis. 
Reports comparing UV-A1 and NB-UVB are ambivalent [15]. Some of them point to 
superiority of NB UV-B, other do not show statistically significant differences [20]. 
In some cases NB UV-B can be combined with UV-A1 in one therapy schedule with 
satisfying clinical effect [21].
In literature there is strong evidence proving efficacy of AD therapy using 
NB-UVB. In a study with a test group of 21 adults with severe course of the disease, 
administering air-conditioned NB-UVB thrice a week for twelve weeks caused 
reduction of severity (68%) and reduction of topical corticosteroid application 
(88%). 15 of 21 patients showed positive result 24 weeks after therapy ended [12]. 
Brazzelli et al. in their study reported efficacy of treating AD with NB UV-B, 
proceeded by oral short-term cyclosporin A (four weeks) and four-six-week-long 
washout phase. Radiation was administered three times a week and lasted up to 
two months [22]. There were some studies concerning NB UV-B therapy of atopic 
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dermatitis in children. Jury et al. in their retrospective trial on 25 children with AD 
showed almost total reduction of lesions in 17 patients [23]. NB-UVB is a recom-
mended therapeutic option in pregnancy [24].
Prospective clinical trial with 29 children (3–16 years old) pointed 61% reduc-
tion in SASSAD score (Six Area Six Sign Atopis Dermatitis) in a group exposed 
to NB UV-B radiation in comparison to untreated patients (P < 0.05). Moreover, 
children without therapy experienced a decrease in the quality of life with a rise of 
disease severity [25].
3.2 UVA1
Development of UVA1 (340-400 nm) lamps was a response to appearing side 
effects, such as long exposure time or risk of sunburn when using UVA-2 (320-340 nm) 
radiation. UVA-1 penetrates deeper into the dermis than UVA-2 and UVB [26]. We 
distinguish different types of doses:
• high dose (80–130 J/cm2),
• medium dose (40–80 J/cm2)
• low dose (<40 J/cm2) [27, 28].
It should be mentioned that a huge inconvenience of UV-A1 in high dose is 
overheating of the device, which can be unsafe. Studies showed that UV-A1 is more 
efficient in AD therapy and has higher efficacy than UV-AB. Krutmann et all proved 
that UV-A1 phototherapy effectiveness is approximately the same as therapy with 
fluocortolone [28]. Medium doses of UVA-A1 have the advantage over high doses 
of UVA-A1 when it comes to reducing adverse drug events and enhancing toler-
ance. The effectiveness and relapse time do not differ strongly between these two 
options of therapy. Therefore the UVA-A1 radiation should be the preferable one 
[1]. UVA-A1 in low doses is practically ineffective, thereby it is not considered to be 
a therapeutic agent [28]. Common treatment schedules of UVA-A1 at medium dose 
(maximum 80 J/cm2) in atopic dermatitis therapy are 3–5 sessions every 3–8 weeks. 
Patient should spend 10 minutes to 1 hour in every phototherapy session [15, 29]. 
Speaking of acute cases of AD, using UV-A1 radiation is more suitable, comparing 
to UV-B [15]. Majoie et al. examined 13 adults (20–56 years old) suffering from 
chronic atopic dermatitis in a randomized investigator-blinded trial and proved 
that NB-UVB and medium dose of UVA1 are comparably efficient in the reduction 
of AD symptoms [20]. The disadvantage of UV-A1 therapy is the cost and the size 
of UV-A1 lamps. Moreover, they demand a presence of ventilation machines, what 
could be financially unachievable for some centers [30]. To meet the expectations 
of the patients engineers created a filter to eliminate wavelengths above 530 nm and 
disperse the excessive heat. It is called Cold-light UV-A1 and it is consider a more 
effective option than UV-AB and classic UV-A1 in treatment of AD flares [31].
3.3 PUVA
PUVA (psoralen and ultraviolet A) is a combination of UVA light and psoralens – 
a substance causing photosensitizing effect. Nowadays in use there is an 8-methoxy-
psoralen (8-MOP), which leads to permanent damage of DNA [13]. Psoralens are 
available in many various formulations, such as pills, cream or bath lotion [32]. In 
bath-PUVA, the patient is taking a bath in warm water with 8-MOP 20–30 minutes 
before UVA session. In case of choosing cream formulation, the regimen is conducted 
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30–60 minutes before radiation [32]. Using topical psoralens could be desired, for 
example in patients with strictly localized lesions. In literature it is proven that PUVA 
phototherapy could be a successful form of atopic dermatitis therapy [33]. Although, 
we should remember that in comparison with other inflammatory diseases treated 
by PUVA, in atopic dermatitis patients require more phototherapy sessions [15]. 
Der-Petrossian M. et al. in a randomized trial compared PUVA bath therapy with NB 
UV-B – there were no significant differences between these types of phototherapy 
[33]. In another study Tzaneva S. et al. showed that after PUVA therapy (using oral 
5-methoxypsoralen, 5-MOP) patients had longer remission times and higher change 
in AD scoring compared to UV-A1 phototherapy [34]. Heinlin et al., in his random-
ized and placebo-controlled trial demonstrated superiority of balneophototherapy 
and NB-UVB combination over only NB-UVB. Patients’ complex therapy had higher 
reduction of SCORAD score not only at the end of treatment, but also after 6 months. 
(P respectively <0,004 and < 0,04) [16]. Because of mutagenic properties of PUVA 
therapy, it should be reminded that it could not be a chronic form of therapy and 
using it should be limited [30].
3.4 UVA/B combination
UVA and UVA combination (280-400 nm) can be conducted by using special 
machines emitting these UV spectrums or as two separate sessions. In clinical trial 
Valkova and Velkova proved that combination UVA/B phototherapy with topical 
corticosteroids reduced the treatment duration significantly in comparison to only 
UVA/B (P = 0.02) [35]. Grandulad et al. investigated reduction of SCORAD, days 
in remission and the improvement in quality of life using ciclosporin and UVA/B. 
Ciclosporin had statistically significantly better scores compared to UVA/B photo-
therapy sessions [36]. Jekler [37] and Larko [38] showed that using the combination 
of UVA/B radiation is more effective than monotherapy of UVA or UVB.
3.5 Excimer laser
Monochromatic excimer laser (MEL) is a kind of single-wavelength light 
source of 308 nm. The advantage of this therapy is a frequency of sessions – every 
7–15 days [39]. MEL could be used on the localized skin lesions. One study showed 
good ability of alleviation of prurigo in AD. However, further clinical trials are 
needed [40].
3.6 Blue light
Blue light (400-495 nm) is a novel therapeutic option. Becker et al. in his 
observational study showed that using blue light devices could the suitable in treat-
ment severe atopic dermatitis. In addition, it provided to long term improvement. 
Observed adverse effects were mild and transient – redness, warmth or itching 
the skin. [41] Kromer et al. is performing a multicenter, prospective randomized, 
placebo controlled, double blinded trial with 150 patients suffering from AD to 
investigate effectiveness of blue light devices. Currently there are no official results, 
but that investigation appears to be promising [42].
4. Side effects
Like every therapeutic agent, phototherapy may cause some side effects. Most 
of them are mild and short-term, for example skin burning (connected with wrong 
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dosage of UV or inadequate radiation schedule), pruritus, hyperpigmentation, dry-
ness and tenderness. Induction of polymorphic light eruptions and viruses reinfec-
tion (such a herpes simplex) are also observed. When it comes to long-term adverse 
effects, photo-aging and induction of cutaneous malignancies can occur [14]. These 
cutaneous malignances can be caused by combing UV radiation with other thera-
peutic factors. There is a reported case of a melanoma diagnosis in a patient with 
mastocytosis who was treated with UVA1 and PUVA bath therapy previously [42]. 
In literature we can find two cases of Merkel cell carcinoma after UVA1 therapy in 
patients who were treated with immunosuppressants for blood dyscrasias [43].
Lately new therapeutic options were presented. One of them is 308 nm 
monochromatic excimer light. It is dedicated for patients with localized and 
therapy-resistant lesions [44]. In comparison to other immunosuppressive agents, 
phototherapy has a better safety profile, adverse effects are milder and better-
tolerated [23]. PUVA systemic therapy can cause hepatotoxicity, nausea, vomiting, 
cataract, long-term photosensitivity and probable skin cancer. Topical use of 
psoralens can limit or help avoid these inconveniences. [45]. However, please note 
that atopic dermatitis is a chronic and recurrent disease which implicates many 
phototherapy sessions and increases the risk of carcinogenesis [16]. Many clinical 
trials showed that phototherapy in children with AD is effective and, in most cases, 
well tolerated. There is, nonetheless, high risk of photocarcinogenesis. In younger 
patients long-term maintenance therapy should be conducted in as short time as 
possible [23]. In conclusion, this way of AD treatment is one of the last therapeutic 
options. Claustrophobia and lack of cooperation is typical for small children and it 
has to be taken into consideration as a challenge in this kind of therapy [15]. Despite 
this, in children with refractory or severe atopic dermatitis we may consider using 
phototherapy. Generally, in such cases, NB UV-B is a therapy of choice and PUVA 
should be avoided [23]. It should be also remembered that there are no randomized 
trials of phototherapy of AD in pregnancy [30]. UV treatment require specific 
amount of time and availability, which can be problematic for patients who are 
attending school or have strict work hours. To meet these demands, there are some 
home phototherapy devices accessible.
5. Conclusions
Phototherapy is considered as a safe and successful therapy in management 
of atopic dermatitis. When topical corticosteroids and calcineurin inhibitors are 
ineffective, phototherapy could be considered as a second line treatment, whether 
in combination with systemic drugs or without them. The most effective types 
of phototherapy are UVA1 and NB-UVB; UVA1 should be pondered in acute 
flares whereas NB-UVB in recurrent atopic dermatitis. In children and pregnancy 
NB-UVB has a good safety profile. Using UVA1 medium dose of radiation has an 
advantage over others. Due to safety profile narrow-band UVB is favored over 
broad-band UVB. Potential adverse effects are usually mild and transient, although 
the risk of carcinogenesis should be always considered.
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